JAZZ Stock Recent News

The rollercoaster ride of the cannabis market has left many in the investing world dazed and confused. The sector's volatility is marked by winds of optimism followed by spells of disappointment.

Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Meeting presentations underscore the increased need for awareness around the cardiovascular and cardiometabolic comorbidities and modifiable risk factors associated with sleep disorders Fourteen abstracts demonstrate Jazz Pharmaceuticals' continued leadership and commitment to expanding knowledge across rare sleep disorders DUBLIN , Oct. 18, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present 14 abstracts from across its sleep medicine portfolio, including two oral presentations, at the 17th annual World Sleep 2023 Congress, held October 20-25 in Rio de Janeiro, Brazil. The oral presentations include findings from the real-world TENOR study, which demonstrated individualized dosing strategies for twice-nightly oxybate treatment in narcolepsy.

Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

The approval is based on data from a phase II/III study, which showed that treatment with Jazz's (JAZZ) Enrylaze achieved sustained asparagine activity in two cancer indications.

DUBLIN , Sept. 13, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in three upcoming investor conferences.

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

The global pharmaceutical cannabis market is poised for significant growth, projected to swell by 23% by 2027, mostly from one company but with other contenders battling to enter the market. In 2023, sales of prescription drugs containing cannabis are estimated to total US$1.11 billion, according to a new report by Prohibition Partners, with sales of currently approved drugs seen expanding to US$1.37 billion.

Jazz Pharmaceuticals and Innovative Industrial Properties have been standouts in the cannabis industry. Both companies have been able to sidestep issues that plague their peers in the industry.

The consensus price target hints at a 51.7% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.